Comparison the Effect of Niacin Treatment with and without Atorvastatin on Lipid Profile in Type 2 Diabetic Patients

Mohammad Afkhami-Ardekani¹, Mahmood Emami-Meibodi², Naimeh Mostafae³,
Arezoo Afkhami-Ardekani⁴*, Boshra Najafi⁵

Abstract

Objective: The risk of cardiovascular disease increased in diabetic patients due to lipoprotein metabolism disorder and insulin resistance. There is different type of dyslipidemia in diabetic patient. The nicotinic acid (niacin) is categorized as vitamin B family and decreases low-density lipoproteins (LDL) and triglyceride (TG) level and increases high-density lipoproteins (HDL). The aim of this study was to compare the effect of niacin treatment with and without atorvastatin on lipid profile on diabetic patient.

Materials and Methods: This study is cross over clinical trial on 30 diabetic patients (9 men, 21 women) referred to diabetes research center of Yazd (IRAN). At initiation of study administered atorvastatin alone (20 mg/day) for 6 weeks (protocol A), and after 3 weeks washout period, started atorvastatin (20 mg/day) with niacin (50 mg/day) for 6 weeks (protocol B). Statistical analysis was accomplished by using SPSS for windows, version 11.50 and kappa and paired T-test.

Results: Patients on protocol B had statistically significant more increase of HDL-C ($P$-value = 0.08) and decrease of TG than profile A ($P$-value = 0.024). Also, 2 hours post prandial blood sugar and HbA1c changes in two groups were not significant A ($P$-value = 0.226), B ($P$-value = 0.918). Patient in group B had statistically significant decrease in systolic blood pressure and diastolic blood pressure than group A ($P$-value = 0.010, $P$-value = 0.015).

Conclusion: This study showed decrease of TG, LDL-C and total cholesterol and increase of HDL in both groups. There are significant changes in HDL-C and TG in group B that used niacin with atorvastatin than group A.

Keywords: Niacin, Atorvastatin, Type 2 diabetes mellitus, Lipid profile

Introduction

The prevalence of type 2 diabetes mellitus (T2DM) over 30 years is about 14.2% in Yazd (1). Nicotinic acid (niacin) is one of the vitamin B groups that decreases low - density lipoproteins (LDL-C) and triglyceride (TG) level and increases high-
density lipoproteins (HDL-C) (2-10). It is the effective drug to increase or HDL-C level and the best drug to decrease of lipid that effect on plasma lipoprotein a (LP-a) level. The niacin is useful for the patient with mixed hyperlipidemia and low LDL-C level (11-14). "The Arterial Disease Multiple Intervention Trial (ADMIT) was a prospective, placebo-controlled study". ADMIT evaluated the healthy and effect of a combination of HDL-C elevating, antioxidant vitamin, and low-dose warfarin therapy on atherosclerotic vascular disease risk factors in patients with peripheral arterial disease and diabetes. Niacin can increase HDL levels due to increasing HDL-cholesterol and decreased TG (15-18). The high risk of cardiovascular disease in diabetic patients depended to lipoprotein metabolism disorder or resistance of insulin (13-20). Lipid metabolism disorder and plasma lipoprotein are the risk factors of atherosclerosis (20-33). Decrease of HDL-C is the risk factor of cardiovascular disease. HDL-C decrease of 1mg/dl causes increase of coronary arterial disease (34). The goal of this study was to compare the effect of niacin treatment with and without atorvastatin on lipid profile in T2DM patients.

Materials and Methods
This study is a clinical trial with cross-over method on thirty T2DM patients (9 men, 21 women) referred to Yazd diabetic research center with specific criteria. The inclusion criteria included: patient with dyslipidemia (total cholesterol > 200, LDL-C >100, TG >150, HDL-C>50 (woman) and HDL-C > 40 (men), HbA1c <10, no statin medication in past 1 month.

The exclusion criteria were patient who did not use drugs and did not come to center routinely. In according to cross-over method; at first atorvastatin (20 mg/day) medication was done in 6 weeks (protocol A) and after 3 weeks as wash out period then atorvastatin (20 mg/day) with niacin (50 mg/day) for 6 weeks (protocol B) were used. Data gathering was done with a check list included demographic subject, duration, complication (nephropathy, retinopathy, neuropathy, diabetic foot) and controlling of diabetes, lipid profile (TG, total cholesterol, LDL, HDL) and lab test (HbA1c, 2HPP, FBS, ALT, AST) and drug complication (dyspepsia, headache, myalgia, sever myopathy, hepatitis, rhabdomyolysis, skin flashing) before and after treatment.

Statistical analysis
Statistical analysis was doing by using SPSS for Windows, version 11.50 and kappa and paired test. Data of continuous variables showed as mean ± standard deviation. Differences between groups were showed by the paired sample tests. Statistical significance was set at P-value< 0.05.

Ethical considerations
This study was approved by Azad Islamic University of Yazd as the doctor of medicine (MD) (Code: IR.10510101852023).

Results
Thirty (30) T2DM patients finished the study. The mean age of patients was 52.3 (± 4.5) years old with mean weight 72.4 (± 12.2) kg, height 158.1 (± 9.4) cm, waist circumflex 103.7 (± 8.9) cm, hip circumflex 101.8 (± 5.6) cm, body mass index (BMI) 28.9 (± 4.5) kg/m2, waist/hip ratio1.01 (± 0.01) and duration of diabetes 6.1 (± 3.7) years. Seventeen (56.6%) of patients have neuropathy and 6 (20%) of them have retinopathy and one (3.33%) of them has diabetic foot (Table 1).

Patients that treatment with protocol A and B have significant decrease in TG, total cholesterol, LDL-C and increase of HDL-C (P-value= 0.009). Patient who were treated with protocol A (only atorvastatin) were statistically significant for decrease total cholesterol (P-value= 0.009) and LDL (P-value= 0.016) than profile B (niacin with atorvastatin). Subjects who were treated with profile B were statistically significant in increase of HDL and decrease of TG than
Comparison the effect of niacin treatment with and without atorvastatin

profile A ($P$-value $= 0.08$, $P$-value $=0.024$) (Table 2,3).

This study analysis changes of lipid profile in according to BMI in two groups. Patients with normal weight (BMI $< 25$) and over weight (BMI $= 25-30$) in group A is statistically significant decrease in total cholesterol than group B ($P$-value $= 0.046$, $P$-value $= 0.027$) Obese patient (BMI $> 30$) in group B is statistically significant increase of HDL and decrease of TG than group A ($P$-value $= 0.000$, $P$-value $= 0.010$). Means of changes lab tests are FBS 13.3 ($±$ 8) (5.3%), 2hpp 31 ($±$ 4.7) (2.2%), HbA1c 0.7 ($±$ 0.3) (3.5%) in profile A and FBS 12.8 ($±$ 4.9) (3.3%), 2hpp 17.2 ($±$ 4) (1.8%), HbA1c 1.0 ($±$ 0.4) (1.2%) in profile B that statistically significant decrease of FBS in profile A ($P$-value $= 0.000$). 2hpp and HbA1c changes in two group is not significant A ($P$-value $= 0.226$), B ($P$-value $= 0.918$). Patient in group B is statistically significant decrease in SBP and DBP than group A ($P$-value $= 0.010$, $P$-value $= 0.015$) and the changes is less than 5 mmHg and not significant. Complication include sever myopathy, rhabdomyolysis, myalgia, arthralgia, increase of ALT and AST was not detected in any patient. Skin flashing (26.7%), dyspepsia (6.7%) and headache (3.3%) were detected.

Discussion

This study showed Patients treated only by atorvastatin were statistically significant for decrease total cholesterol ($P$-value $= 0.009$)

| Table 1. Baseline characteristic and biochemical markers of patients |
|---------------------------------------------------------------|
| Variables | Mean ($±$ SD) |
| BMI (Kg/m²) | 28.9 ($±$ 4.5) |
| FBS (mg/dl) | 148 ($±$ 20.3) |
| 2hpp (mg/dl) | 211 ($±$ 38.3) |
| HbA1C % | 8.4 ($±$ 1.3) |
| TG (mg/dl) | 94.6 ($±$ 33.3) |
| Cholesterol (mg/dl) | 299 ($±$ 50.2) |
| LDL (mg/dl) | 191.7 ($±$ 44.1) |
| HDL (mg/dl) | 39.6 ($±$ 12.3) |
| Systolic blood pressure (mm/Hg) | 130.8 ($±$ 16.6) |
| Diastolic blood pressure (mm/Hg) | 75.8 ($±$ 9.5) |

| Table 2. Biochemical parameters before and after atorvastatin consumption |
|---------------------------------------------------------------|
| Variables | Pre-trial Mean ($±$ SD) | Post-trial Mean ($±$ SD) | $P$-value* |
| FBS (mg/dl) | 148.3 ($±$ 20.3) | 140.3 ($±$ 19.1) | 0.003 |
| 2hpp (mg/dl) | 211.9 ($±$ 38.3) | 207.2 ($±$ 37.6) | 0.410 |
| HbA1C % | 8.4 ($±$ 1.3) | 8.1 ($±$ 1.2) | 0.032 |
| TG (mg/dl) | 330.3 ($±$ 92.1) | 235.8 ($±$ 65.8) | 0.0001 |
| Cholesterol (mg/dl) | 299.6 ($±$ 50.2) | 202.6 ($±$ 44.1) | 0.0001 |
| LDL (mg/dl) | 191.7 ($±$ 44.1) | 103.6 ($±$ 21.4) | 0.0001 |
| HDL (mg/dl) | 39.6 ($±$ 12.3) | 44.8 ($±$ 13.6) | 0.0001 |
| Systolic blood pressure (mm/Hg) | 130.8 ($±$ 16.6) | 128.1 ($±$ 11.3) | 0.016 |
| Diastolic blood pressure (mm/Hg) | 75.8 ($±$ 9.5) | 74.3 ($±$ 8.5) | 0.402 |

*paired T-test

| Table 3. Biochemical parameters before and after atorvastatin and niacin consumption |
|---------------------------------------------------------------|
| Variables | Pre-trial | Post-trial | $P$-value* |
| FBS (mg/dl) | 145.5 ($±$ 26.3) | 150.4 ($±$ 19.4) | 0.044 |
| 2hpp (mg/dl) | 213.5 ($±$ 37.6) | 209 ($±$ 35.8) | 0.214 |
| HbA1C % | 8.3 ($±$ 1.2) | 8.2 ($±$ 1.1) | 0.232 |
| TG (mg/dl) | 308.2 ($±$ 78.8) | 202 ($±$ 49.9) | 0.0001 |
| Cholesterol (mg/dl) | 275.7 ($±$ 38.2) | 181.1 ($±$ 21.4) | 0.0001 |
| LDL (mg/dl) | 173.7 ($±$ 30.8) | 92.5 ($±$ 18.2) | 0.0001 |
| HDL (mg/dl) | 417 ($±$ 11.8) | 48.6 ($±$ 13.4) | 0.0001 |
| Systolic blood pressure (mm/Hg) | 131.3 ($±$ 15.5) | 127.2 ($±$ 14.9) | 0.087 |
| Diastolic blood pressure (mm/Hg) | 78 ($±$ 7.6) | 74.8 ($±$ 8.03) | 0.049 |

*paired T-test
and LDL-C (P-value= 0.016) than patients treated with niacin and atorvastatin. Patients treated with atorvastatin plus niacin were statistically significant increase of HDL and decrease of TG than group give only atorvastatin (P-value= 0.08, P-value= 0.024). Lipid lowering drug use is an essential method in both patients with peripheral arterial disease and diabetic patients to reduce the risk of atherosclerotic vascular disease (13,16), in spite of ability of Niacin to increase HDL-C and lower triglycerides, the use of niacin has been weaken in patients with diabetes,(10-13) due to increasing of glycemic control in patients with and without diabetes who were treated with niacin (3,17-19).

Many article reports of niacin-induced glucose intolerance are performing on uncontrolled diabetic patients (17-20). Many of these studies were performed on patients without diabetes (18-20) and some studies conducted on patients with diabetes (3,17,21,22). One of another study showed niacin high withdrawal rates because poor glycemic control in patients with diabetes on slow-release niacin. These data may also present a difference between sustained release and crystalline (immediate release) (23).

Many studies showed decreased glucose tolerance and increased plasma insulin levels in person without diabetes after niacin administration (18,19,22-24). A study showed minimum effect of niacin administration on insulin levels and glucose in normal person (25).

For treatment of dyslipidemia in type 2 diabetes mellitus suggested offensive lipid lowering statin drugs or fibrates (12). Though LDL-C is suggested as the first goal of treatment, it is visible that hypertriglyceridemia and decreased HDL-C are very common in type 2 diabetes mellitus, and are with increased risk of atherosclerotic vascular disease (10,13). Niacin reduces plasma triglycerides by reducing hepatic production of VLDL, and increases HDL-C by up to 30%, by reducing hepatic removal of apolipoprotein A-1 (26-27). Niacin also reduces plasma LDL-C by 10% to 15% (28). Though the LDL-C lowering of niacin may be compared with that of statin drugs, niacin has a biggest effect on HDL-C, triglycerides, and lipoprotein (a) (4). In many patients with diabetes, treatment with gemfibrozil and niacin may be need to be lower triglycerides to goals (29).

There is bounded data about lipid-modifying interventions reduce benefit for patients with diabetes for lowering cardiovascular morbidity and mortality .The Scandinavian Simvastatin Survival Study referred that patients with diabetes may be reduce coronary artery disease with simvastatin (30). In the Helsinki Heart study, patients with diabetes experienced a 60% reduction in coronary artery disease with gemfibrozil (31). In the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT), patients with diabetes may be reduce coronary artery disease with gemfibrozil (32).

In spite presence of some information about disagreeing use of niacin in diabetes (10,12) the present study suggested lipid lowering doses of immediate-release niacin can be used safely in patients with type 2 diabetes mellitus. Niacin therapy may be supplanted as recurring to statin or fibrates in patients with diabetes fail to enough effect on hypertriglyceridemia or HDL-C increasing. Remarkably in cases of lack of effect of statin and fibrates drugs, Niacin may be considered first drug for treatment of diabetic dyslipidemia.

There are many drugs used for control of lipid and the best of them is most effective in decrease of cholesterol and LDL-C and increase of HDL-C. The combination therapy is used for patient with both hypertriglyceridemia and hypercholesterolemia that not control with one drug or high LDL-C and low HDL-C. The use of niacin and statin are very helpful for patient with LDL-C that not controlled by statin and HDL-C is below 40 mg/dl. Patient with hyperlipidemia (hypertriglyceridemia and hypercholesterolemia) that treated by fibrate do not reach normal LDL-C level and this patients are candidate for statin added to their treatment that can slightly increase HDL-C
level (5 -10%), although fibrate effect on HDL-C (increase 5 – 10%) but niacin is more effective for increase of HDL-C (30%) (33).

Conclusions
There were statistical significance decrease of TG, LDL-C and total cholesterol and increase of HDL-C in both groups. There were significant changes in HDL and TG in group B than group A. There were no any drug complication in two groups.

Conflict of Interest
The authors declared that they have no conflict of interests.

References
1. Afkhami Ardakani M, Vahidy S, Vahidy E, Ahmadiyah M.H. A Study of The Epidemiological Factors of Diabetes mellitus in Adults aged >30 years in Yazd in 1998, The Journal of Shahid . Sadoughi University of Medical Sciences, Yazd.2001;9(1):22-27.(in Persian)
2. Knopp RH, Ginsberg J, Albers JJ, Hoff C, Ogilvie JT, Warnick GR, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism-Clinical and Experimental. 1985;34(7):642-50.
3. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. Journal of the American Medical Association. 1990;264(6):723-6.
4. Illingworth DR, Stein EA, Mitchel YB, Dujovne CA, Frost PH, Knopp RH, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia: a prospective trial. Archives of internal medicine. 1994;154(14):1586-95.
5. Clofibrate and niacin in coronary heart disease. Journal of the American Medical Association. 1975:231:360-381.
6. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. Journal of the American College of Cardiology. 1986;8(6):1245-55.
7. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. New England Journal of Medicine. 1990;323(19):1289-98.
8. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. Jama. 1987;257(23):3233-40.
9. Gordon T, Kannel W. Predisposition to atherosclerosis of the head, heart and legs: the Framingham Study. Journal of the American Medical Association 1972;221:661-666.
10. Garg A. Lipid-lowering therapy and macrovascular disease in diabetes mellitus. Diabetes. 1992;41:111-115.
11. Oki JC. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 1995;15(3):317-37.
12. Haffner SM. American Diabetes Association: Management of dyslipidemia in adults with diabetes. Diabetes care. 2003;26(1):83-6.
13. Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes care. 1998;21(1):160-78.
14. Egan DA, Garg R, Wilt TJ, Pettinger MB, Davis KB, Crouse J, et al. Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study. The American journal of cardiology. 1999;83(4):569-75.
15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical chemistry. 1972;18(6):499-502.
16. Grundy SM, Bilheimer D, Chait A, Clark LT, Denke M, Havel RJ, et al. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Journal of the American Medical Association. 1993;269(23):3015-23.
17. Molnar GD, Berge KG, Rosevear JW, McGuckin WF, Achor RW. The effect of nicotinic acid in diabetes mellitus. Metabolism. 1964;13(2):181-90.
18. Kahn SE, Beard JC, Schwartz MW, Ward WK, Ding HL, Bergman RN, et al. Increased β-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes. 1989;38(5):562-8.
19. Gaut ZN, Pocelinko R, Solomon HM, Thomas GB. Oral glucose tolerance, plasma insulin, and uric acid excretion in man during chronic administration of nicotinic acid. Metabolism. 1971;20(11):1031-5.
20. Miettinen TA, Taskinen MR, Pelkonen R, Nikkilä EA. Glucose tolerance and plasma insulin in man during acute and chronic administration of nicotinic acid. Acta Medica Scandinavica. 1969;186(1-6):247-53.
21. Parsons WB. Studies of nicotinic acid use in hypercholesteremia: Changes in hepatic function, carbohydrate tolerance, and uric acid metabolism. Archives of internal medicine. 1961;107(5):653-67.
22. Gurian H, Adlesberg D. The effect of large doses of nicotinic acid on circulating lipids and carbohydrate tolerance. American Journal of Medical Sciences. 1959;237:12-22.
23. Gray DR, Morgan T, Chretien SD, Kashyap ML. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Annals of internal medicine. 1994;121(4):252-8.
24. Tornvall P, Walldius G. A comparison between nicotinic acid and acipimox in hypertriglyceridaemia-effects on serum lipids, lipoproteins, glucose tolerance and tolerability. Journal of internal medicine. 1991;230(5):415-21.
25. Alvarsson M, Grill V. Impact of nicotinic acid treatment on insulin secretion and insulin sensitivity in low and high insulin responders. Scandinavian journal of clinical and laboratory investigation. 1996;56(6):563-70.
26. Grundy SM, Mok HY, Zech L, Berman M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. Journal of lipid research. 1981;22(1):24-36.
27. Jin FY, Kamanna VS, Kashyap ML. Niacin decreases removal of high-density lipoprotein apolipoprotein AI but not cholesterol ester by Hep G2 cells: implication for reverse cholesterol transport. Arteriosclerosis, thrombosis, and vascular biology. 1997;17(10):2020-8.
28. Knopp RH. Drug treatment of lipid disorders. New England Journal of Medicine. 1999;341(7):498-511.
29. Garg A, Grundy SM. Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia in NIDDM. Diabetes. 1989;38(3):364-72.
30. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes care. 1997;20(4):614-20.
31. Koskinen P, Mänttäri M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes care. 1992;15(7):820-5.
32. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. New England Journal of Medicine. 1999;341(6):410-8.
33. Tinsley .R .Harrison. Harrison's principles of internal medicine (metabolic and endocrine disorder) 16th Ed, 2005, 223-290; 551-557.
34. Cheung MC, Zhao XQ, Chait A, Albers JJ, Brown BG. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arteriosclerosis, thrombosis, and vascular biology. 2001;21(8):1320-6.